Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Innovation Council · Running

NumiMilk NūmiMilk: Transforming infant nutrition through mammalian cell bioproduction.

Coordinator
Mumilk, France
Runs
1 October 2026 to 30 September 2028
Status
Running
EU funding
€2.5m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101315105

What the project is doing

In the project's own words, from its summary on CORDIS.

Human breast milk is the ideal nutrition for infants, containing over 1,500 bioactive molecules essential for immune, intestinal, and brain development. Formula-fed infants, especially preterm, face higher risks of infections, allergies, and metabolic diseases due to missing these components. Despite WHO recommendations, exclusive breastfeeding rates remain low globally, hindered by medical, lifestyle, and cultural barriers.

Current alternatives, such as cow’s milk-based, hydrolysed, and plant-based formulas, fail to match breast milk’s complexity, often lacking key nutrients and raise allergy and environmental concerns. Nūmi is the first European biotech company to produce human breast milk and its key components ex vivo by cultivating human mammary cells in bioreactors. Through 3D organoid cell culture, Nūmi can produce a full spectrum of human milk constituents in their native form.

Our goal is to provide optimal infant nutrition when breastfeeding is not possible or desired, and to supply high-value ingredients at scale and at an affordable cost. Our initial target is the €89B infant formula market, beginning with high-value B2B ingredients such as protein mixes and HMO blends, and progressing toward more complex formulations. Looking ahead, the benefits of breast milk constituents extend well beyond infancy, unlocking opportunities in the €133B adjacent specialised nutrition markets.

EIC funding will enable us to accelerate upstream bioproduction scale-up, enhance downstream purification processes, expand our portfolio through ingredient diversification, and achieve industrial-scale manufacturing. This support is crucial for bringing our innovative solutions to market efficiently and ensuring that safe, high-quality human milk-derived ingredients are accessible for infant nutrition and beyond.

Topics

Who is involved

OrganisationCityCountryRole
MumilkEvry-CourcouronnesFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI